ResearcherStony Brook UniversityNo recent work listed

Yue Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0789-4970; OpenAlex author ID A5100333680. Sources: OpenAlex.

Their work

Papers: 4
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper

Papers 4

18F-FDG-PET/CT-based deep learning model for fully automated prediction of pathological grading for pancreatic ductal adenocarcinoma before surgery. Co-author DOI 10.1186/s13550-023-00985-4 ↗
Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2022.942154 ↗
Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. Co-author DOI 10.1186/s40164-015-0025-y ↗
Immune Therapy in Pancreatic Cancer: Now and the Future? Co-author DOI 10.2174/1574887110666150916142537 ↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zizheng Wang · 1 shared paper, 2023 · strength 0.18
- Paper 18F-FDG-PET/CT-based deep learning model for fully automated prediction of pathological grading for pancreatic ductal a… DOI 10.1186/s13550-023-00985-4 ↗
Fei Wang · 1 shared paper, 2023 · strength 0.18
- Paper 18F-FDG-PET/CT-based deep learning model for fully automated prediction of pathological grading for pancreatic ductal a… DOI 10.1186/s13550-023-00985-4 ↗
Gong Zhang · 1 shared paper, 2023 · strength 0.18
- Paper 18F-FDG-PET/CT-based deep learning model for fully automated prediction of pathological grading for pancreatic ductal a… DOI 10.1186/s13550-023-00985-4 ↗
Yanzhe Liu · 1 shared paper, 2023 · strength 0.18
- Paper 18F-FDG-PET/CT-based deep learning model for fully automated prediction of pathological grading for pancreatic ductal a… DOI 10.1186/s13550-023-00985-4 ↗
Rong Liu · 1 shared paper, 2023 · strength 0.18
- Paper 18F-FDG-PET/CT-based deep learning model for fully automated prediction of pathological grading for pancreatic ductal a… DOI 10.1186/s13550-023-00985-4 ↗
Jie Chen · 1 shared paper, 2022 · strength 0.17
- Paper Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic du… DOI 10.3389/fimmu.2022.942154 ↗
Xianlong Chen · 1 shared paper, 2022 · strength 0.17
- Paper Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic du… DOI 10.3389/fimmu.2022.942154 ↗
Shuangni Yu · 1 shared paper, 2022 · strength 0.17
- Paper Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic du… DOI 10.3389/fimmu.2022.942154 ↗
Minsig Choi · 1 shared paper, 2015 · strength 0.11
- Paper Immune Therapy in Pancreatic Cancer: Now and the Future? DOI 10.2174/1574887110666150916142537 ↗
Stacey Stein · 1 shared paper, 2015 · strength 0.07
- Paper Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospe… DOI 10.1186/s40164-015-0025-y ↗
Jill Lacy · 1 shared paper, 2015 · strength 0.07
- Paper Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospe… DOI 10.1186/s40164-015-0025-y ↗
Howard S. Höchster · 1 shared paper, 2015 · strength 0.07
- Paper Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospe… DOI 10.1186/s40164-015-0025-y ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.